Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles.
Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.
